# B. Riley Financial Type: Company Source: GetYourBrief — https://getyourbrief.com/entity/b-riley-financial Canonical HTML page: https://getyourbrief.com/entity/b-riley-financial ## Timeline - **2026-08-16**: Wall Street Zen upgrades both stocks — Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold. - **2026-08-14**: Friday trading close — AMPY opened at $4.78 and BRSP opened at $5.00. - **2026-08-11**: Benchmark and Weiss update AMPY — Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+). - **2026-07-30**: B. Riley trims BRSP target — B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating. - **2026-07-29**: JonesTrading reiterates BRSP buy — JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital. - **2026-07-28**: BrightSpire reports Q2 earnings — BRSP posted EPS of $0.13, missing the $0.15 consensus, with revenue of $48.70 million. - **2026-06-23**: James Frew buys AMPY shares — Insider James Frew acquired 25,000 Amplify Energy shares at an average cost of $3.95 per share. - **2026-05-26**: Weiss lowers BrightSpire Capital — Weiss Ratings lowered BRSP from hold (c-) to sell (d+). - **2026-04-22**: BTIG upgrades BrightSpire Capital — BTIG Research raised BRSP from neutral to buy and set a $7.00 price target. ## Recent coverage (7 stories, network-wide) ### AMPY Upgraded to Hold: $4.78 Stock, $9 Target, 10.6 P/E 2026-08-18 04:52:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name. Full story: https://getfinancebrief.com/story/ampy-wall-street-zen-hold-upgrade-finance ### Agenus Upgraded to Buy After 189% Surge Off 12M Low: Analysts Eye $30 Target 2026-08-08 12:53:05 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology. Full story: https://getbiobrief.com/story/agenus-upgraded-buy-189-percent-surge ### Novavax Cut to Sell by Wall Street Zen as Stock Trades at $7.41 2026-08-04 12:11:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78. Full story: https://gethealthbrief.com/story/novavax-sell-downgrade-wall-street-zen-health ### Wall Street Zen Slaps Sell Ratings on CME, Novavax, and SNDL – 3 Stocks to Watch 2026-08-04 12:11:28 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 In a single day, Wall Street Zen downgraded CME Group to strong sell, and Novavax and SNDL to sell, sending bearish signals across exchanges, biotech, and cannabis. Markets digest the calls amid wide analyst disagreement. Full story: https://getfinancebrief.com/story/wall-street-zen-downgrades-cme-nvax-sndl-finance ### Biotech Sell-Off: Novavax Downgraded to Sell Despite Revenue Beat 2026-08-04 12:11:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Novavax was slapped with a sell rating by Wall Street Zen, even after beating Q1 revenue estimates by 49%. The downgrade highlights biotech skepticism toward small-cap vaccine players in a shifting market. Full story: https://getbiobrief.com/story/novavax-sell-downgrade-biotech-pharma ### Crocs Q3 Guidance Miss: $996.3M Revenue vs. $1B Consensus, Stock Falls 7.4% 2026-07-31 00:49:03 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Crocs, Inc. issued Q3 2026 guidance below expectations, with EPS of $3.20-$3.30 and revenue of $996.3 million, missing the consensus of $3.55 and $1.0 billion, respectively. The shortfall triggered a 7.4% stock decline, raising concerns about softening consumer demand for casual footwear heading into the back-to-school season. Full story: https://getretailbrief.com/story/crocs-q3-2026-guidance-miss ### AXT EPS Soars 210% Above Consensus, Crocs Misses 9%; Divergent Q3 Outlooks 2026-07-31 00:48:55 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 AXT blew past Q3 consensus with EPS guidance of $0.30-$0.32 vs. $0.10 and revenue of $66M vs. $38.7M, while Crocs missed with $3.20-$3.30 EPS vs. $3.55 and $996.3M revenue vs. $1.0B. The split paints a complex picture for investors, highlighting a semiconductor super-cycle amid softening consumer discretionary. Full story: https://getfinancebrief.com/story/axt-crocs-q3-guidance-divergence --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.